More and more Americans are turning to GLP-1 injections to lose weight. FOX 7 Austin's Rebecca Thomas spoke to an Austin ...

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

The supply shortage and high costs of GLP-1 weight loss drugs have created an opportunity for compounded GLP-1 treatments to ...

Researchers looked at the nine people who had vision problems while using the drugs and is one of several that have ...

The beverage giant is ready to manage, mitigate and adjust to the “dynamic macro environment,” including potential tariffs ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — experienced vision issues, including three potentially blinding eye conditions.

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

The spot “is a clear violation” of the FDCA, “which requires that advertising for prescription drugs — including compounded ...